The Role of the Methoxyphenol Apocynin, a Vascular NADPH Oxidase Inhibitor, as a Chemopreventative Agent in the Potential Treatment of Cardiovascular Diseases
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Oxidative stress has been linked to the origin and progression of cardiovascular diseases. Nicotinamide adenine dinucleotide phosphate, reduced form (NADPH) oxidase is a multi-component, NADPH-dependent enzyme that generates superoxide anion in the presence of molecular oxygen. The enzyme has been identified and characterized in all 3 vascular wall cell types and represents the major source of reactive oxygen species (ROS) production in the vascular wall. Inhibition of NADPH oxidase activation appears to suppress the sequence of cellular events that leads to a variety of cardiovascular diseases, including atherosclerosis. The naturally occurring methoxyphenol apocynin has been found to inhibit NADPH oxidase upon activation by peroxidases (e.g. soybean peroxidase, myeloperoxidase) or ROS under mild reaction conditions. Upon peroxidase-catalyzed activation, the apocynin oxidation products act to block the assembly and activation of NADPH oxidase. Although the mechanism of inhibition of NADPH oxidase remains largely unknown, apocynin's high effectiveness and low toxicity makes it a promising lead compound in the development of new therapeutic agents for cardiovascular diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
H 2 O 2 , a Necessary Evil for Cell Signaling
Rhee, S. G. (2006) · Science · doi:10.1126/science.1130481 · Cited by 2,160
Hypercholesterolemia increases endothelial superoxide anion production.
Ohara, Y., Peterson, T. E., & Harrison, D. G. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116491 · Cited by 1,765 · cited 1×
“Atherogenic levels of LDL have been shown to lead to a significant increase in NADPH oxidase dependent ROS production by the endothelium [163].”
BackgroundLandmesser, U., Dikalov, S., Price, S. R., McCann, L., Fukai, T., Holland, S. M., Mitch, W. E., & Harrison, D. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200314172 · Cited by 1,660
Oxidant signals and oxidative stress
Finkel, T. (2003) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(03)00002-4 · Cited by 1,393
Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo
Meng, T.-C., Fukada, T., & Tonks, N. K. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00445-8 · Cited by 1,040
Superoxide Production and Expression of Nox Family Proteins in Human Atherosclerosis
Sorescu, D., Weiss, D., Lassègue, B., Clempus, R. E., Szöcs, K., Sorescu, G. P., Valppu, L., Quinn, M. T., Lambeth, J. D., Vega, J. D., et al. (2002) · Circulation · doi:10.1161/01.cir.0000012917.74432.66 · Cited by 847
Lassègue, B., Sorescu, D., Szöcs, K., Yin, Q., Akers, M., Zhang, Y., Grant, S. L., Lambeth, J. D., & Griendling, K. K. (2001) · Circulation Research · doi:10.1161/hh0901.090299 · Cited by 839 · cited 18×
“There is also some evidence for the involvement of Rho family guanosine triphosphate hydrolases (GTPases) in ROS generation in VSMC, and this is supported in suppression of NADPH oxidase by statins, which inhibit the synthesis of isoprenoids such as farnesylpyrophosphate and geranylgeranylpyrophosphate that are import…”
BackgroundInfluentialThe vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases
Cai, H., Griendling, K. K., & Harrison, D. G. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00233-5 · Cited by 687
Görlach, A., Brandes, R. P., Nguyen, K., Amidi, M., Dehghani, F., & Busse, R. (2000) · Circulation Research · doi:10.1161/01.res.87.1.26 · Cited by 598 · cited 4×
“A number of studies support the presence of a functional NADPH oxidase in EC, which is capable of producing ROS and similar to that of phagocytes [96, 101-107].”
BackgroundResultInfluentialTouyz, R. M., Chen, X., Tabet, F., Yao, G., He, G., Quinn, M. T., Pagano, P. J., & Schiffrin, E. L. (2002) · Circulation Research · doi:10.1161/01.res.0000020404.01971.2f · Cited by 590
Ambasta, R. K., Kumar, P., Griendling, K. K., Schmidt, H. H. H. W., Busse, R., & Brandes, R. P. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406486200 · Cited by 541
Nox4 as the Major Catalytic Component of an Endothelial NAD(P)H Oxidase
Ago, T., Kitazono, T., Ooboshi, H., Iyama, T., Han, Y. H., Takada, J., Wakisaka, M., Ibayashi, S., Utsumi, H., & Iida, M. (2004) · Circulation · doi:10.1161/01.cir.0000105680.92873.70 · Cited by 497
Two Novel Proteins Activate Superoxide Generation by the NADPH Oxidase NOX1
Bánfi, B., Clark, R. A., Steger, K., & Krause, K.-H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c200613200 · Cited by 491
Pagano, P. J., Clark, J. K., Cifuentes-Pagano, M. E., Clark, S. M., Callis, G. M., & Quinn, M. T. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.26.14483 · Cited by 455 · cited 2×
“Fibrobloasts, such as EC, express the flavocytochrome b558 subunits, gp91 and p22, as well as the cytosolic factors p47 and p67 [97].”
BackgroundTwo cytosolic neutrophil oxidase components absent in autosomal chronic granulomatous disease
Volpp, B. D., Nauseef, W. M., & Clark, R. A. (1988) · Science · doi:10.1126/science.2848318 · Cited by 407 · cited 1×
“A functional phagocytic NADPH oxidase complex consists of the membrane-anchored flavocytochrome b558 (a heterodimer composed of gp91 phox and p22), cytosolic proteins p47, p67, and p40, and the low molecular-weight GTP-binding proteins, Rac 1 or 2 [50, 62-66].”
BackgroundInteractions Between Nitric Oxide and Lipid Oxidation Pathways: Implications for Vascular Disease
O’Donnell, V. B., & Freeman, B. A. (2001) · Circulation Research · doi:10.1161/01.res.88.1.12 · Cited by 257
Thomson, L., Trujillo, M., Telleri, R., & Radi, R. (1995) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1995.1321 · Cited by 186
DeLeo, F. R., Yu, L., Burritt, J. B., Loetterle, L. R., Bond, C. W., Jesaitis, A. J., & Quinn, M. T. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.7110 · Cited by 150 · cited 1×
“In addition, three interaction sites are reported to exist between p47 and gp91 [90].”
Background
Cited by
Seimon, T. A., Nadolski, M. J., Liao, X., Magallon, J., Nguyen, M., Feric, N. T., Koschinsky, M. L., Harkewicz, R., Witztum, J. L., Tsimikas, S., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.09.010 · Cited by 457
Rochette, L., Lorin, J., Zeller, M., Guilland, J.-C., Lorgis, L., Cottin, Y., & Vergely, C. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.07.004 · Cited by 456
The NOX toolbox: validating the role of NADPH oxidases in physiology and disease
Altenhöfer, S., Kleikers, P. W. M., Radermacher, K. A., Scheurer, P., Rob Hermans, J. J., Schiffers, P., Ho, H., Wingler, K., & Schmidt, H. H. H. W. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1010-9 · Cited by 371
“Apocynin cannot be used as selective NADPH oxidase inhibitor due to its direct antioxidant and several off-target effects [54–57].”
BackgroundPrediction of Solubility of Drugs and Other Compounds in Organic Solvents
Abraham, M. H., Smith, R. E., Luchtefeld, R., Boorem, A. J., Luo, R., & Acree, W. E. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21922 · Cited by 341
Laleu, B., Gaggini, F., Orchard, M., Fioraso-Cartier, L., Cagnon, L., Houngninou-Molango, S., Gradia, A., Duboux, G., Merlot, C., Heitz, F., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100773e · Cited by 243
Metadata
- Authors
- Yu, J., Weiwer, M., Linhardt, R., & Dordick, J.
- Venue
- Current Vascular Pharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2008-07-01
- Volume
- 6
- Issue
- 3
- Pages
- 204-217
- ISSN
- 1570-1611 (ISSN-L)
- OpenAlex
- W2112188844
- Cited by
- 62
- References
- 18
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.